PMID: 6974887Jul 1, 1981Paper

An attempt to obtain a specific antiserum for in vitro immunological conditioning of bone marrow in acute non-lymphoblastic leukemia

La Ricerca in Clinica E in Laboratorio
C DelfiniG Lucarelli

Abstract

An antiserum was produced in rabbits to acute undifferentiated leukemia (AUL) antigens. Partial absorption of the antiserum allowed the removal of the cytotoxic activity against normal mononuclear cells of peripheral blood and bone marrow, in contrast to blast cells from acute and chronic leukemias, which were killed by the antiserum in a standard NIH cytotoxicity test. These observations suggest that antigens present on blast cells of AUL are also expressed on some acute and chronic leukemic cells and that these antigens could be interpreted as B or leukemia-associated antigens because of the disappearance of all cytotoxic activity of the immune serum after extensive absorption with B cells from chronic lymphoid leukemia.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.